From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

ShareProphets Share Tips of the year number 20: Buy Amryt Pharma says Tom Winnifrith

By Tom Winnifrith | Saturday 31 December 2016


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Boy did Amryt bore its loyal shareholders, including us, to tears for most of 2016. Owning this stock, formerly a failed oil explorer Fastnet, was like watching paint dry. Amid a totally understandable ennui the shares drifted back to lows of just under 14p which - as we had tipped the shares at 18.4p and bought ourselves at higher levels - was a bit of a pain. But then in November it roared into life and the shares are now 18.5p-20.5p and are my second buy tip of the year at up to 22p.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

 

GEX

Georgina Energy: Lyin’ Yet again

Time left: 10:25:25